Completed PHASE3 INTERVENTIONAL NCT00232050

Study of Omalizumab in Moderate to Severe Bronchial Asthma

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Asthma

Interventions Omalizumab

Updated 5 times since 2017 Last updated: Oct 24, 2011 Started: Oct 31, 2002 Primary completion: May 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Asthma and is currently completed. Daiichi Sankyo Co., Ltd. leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.
Novartis

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.